Table II.
Analysis using a Cox proportional hazards regression model for assessing the association between the plasma lactate dehydrogenase level and progression-free survival.
| Variable | HR (95% CI) | P-value |
|---|---|---|
| Stage | 0.59 | |
| III/IV | 1.28 (0.53–3.31) | |
| Recurrence | 1 | |
| EGFR status | 0.03 | |
| Common | 0.30 (0.11–0.90) | |
| Uncommon | 1 | |
| PS | 0.28 | |
| 0–1 | 0.66 (0.32–1.40) | |
| ≥2 | 1 | |
| Brain metastasis | <0.01 | |
| Yes | 3.39 (1.56–7.37) | |
| No | 1 | |
| Liver metastasis | 0.47 | |
| Yes | 1.32 (0.61–2.70) | |
| No | 1 | |
| Pleural effusion | 0.19 | |
| Yes | 1.74 (0.76–3.92) | |
| No | 1 | |
| LDH | 0.05 | |
| <210 | 0.49 (0.24–0.99) | |
| ≥210 | 1 |
EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase; PS, performance status; HR, hazard ratio; CI, confidence interval.